Eccogene

Cambridge, US · 1 known investors

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease. Its pipeline includes GLP-1 receptor agonist, THR-β, and SSAO programs, with its lead asset ECC5004 licensed to AstraZeneca.